ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
DeepInterAware: Deep Interaction Interface-Aware Network for Improving Antigen-Antibody Interaction Prediction from Sequence Data.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evidence-aware comparison of sequence-centric machine learning for antibody discovery and optimization.Briefings in bioinformatics · 2026Article
- Bio-Inspired Mamba for Antibody-Antigen Interaction Prediction.Biomolecules · 2025Article
- RLEAAI: improving antibody-antigen interaction prediction using protein language model and sequence order information.Briefings in bioinformatics · 2025Article
- DeepInterAware: Deep Interaction Interface-Aware Network for Improving Antigen-Antibody Interaction Prediction from Sequence Data.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Identifying interactions between candidate antibodies and target antigens is a key step in developing effective human therapeutics. The antigen-antibody interaction (AAI) occurs at the structural level, but the limited structure data poses a significant challenge. However, recent studies revealed that structural information can be learned from the vast amount of sequence data, indicating that the interaction prediction can benefit from the abundance of antigen and antibody sequences. In this study, DeepInterAware (deep interaction interface-aware network) is proposed, a framework dynamically incorporating interaction interface information directly learned from sequence data, along with the inherent specificity information of the sequences. Experimental results in interaction prediction demonstrate that DeepInterAware outperforms existing methods and exhibits promising inductive capabilities for predicting interactions involving unseen antigens or antibodies, and transfer capabilities for similar tasks. More notably, DeepInterAware has unique advantages that existing methods lack. First, DeepInterAware can dive into the underlying mechanisms of AAIs, offering the ability to identify potential binding sites. Second, it is proficient in detecting mutations within antigens or antibodies, and can be extended for precise predictions of the binding free energy changes upon mutations. The HER2-targeting antibody screening experiment further underscores DeepInterAware's exceptional capability in identifying binding antibodies for target antigens, establishing it as an important tool for antibody screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.